{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:47:37Z","timestamp":1794052057980,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scholar Rock, Inc. funded the trial and drafting of the manuscript."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04157-w","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:01:33Z","timestamp":1768298493000},"page":"992-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy F.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-9702","authenticated-orcid":false,"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-1560","authenticated-orcid":false,"given":"Bruno","family":"Bockorny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar S.","family":"Tirucherai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-5748","authenticated-orcid":false,"given":"Stephen","family":"DeWall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Qatanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing L.","family":"Marantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"4157_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/curroncol31010001","volume":"31","author":"CH Coschi","year":"2023","unstructured":"Coschi, C. H. & Juergens, R. A. Overcoming resistance mechanisms to immune checkpoint inhibitors: leveraging the anti-tumor immune response. Curr. Oncol. 31, 1\u201323 (2023).","journal-title":"Curr. Oncol."},{"key":"4157_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.euf.2023.12.005","volume":"10","author":"MR Hassler","year":"2024","unstructured":"Hassler, M. R. et al. Treatment patterns and real-world outcomes for locally advanced or metastatic urothelial cancer in the era of immunotherapy. Eur. Urol. Focus 10, 779\u2013787 (2024).","journal-title":"Eur. Urol. Focus"},{"key":"4157_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003473","volume":"9","author":"A Tzeng","year":"2021","unstructured":"Tzeng, A., Tzeng, T. H. & Ornstein, M. C. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. J. Immunother. Cancer 9, e003473 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"4157_CR4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4157_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang, B. et al. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Biosci. 13, 120 (2023).","journal-title":"Cell Biosci."},{"key":"4157_CR6","first-page":"454","volume":"3","author":"M Moreira","year":"2020","unstructured":"Moreira, M. et al. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resist. 3, 454\u2013471 (2020).","journal-title":"Cancer Drug Resist."},{"key":"4157_CR7","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMra043172","volume":"353","author":"HT Cohen","year":"2005","unstructured":"Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477\u20132490 (2005).","journal-title":"N. Engl. J. Med."},{"key":"4157_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0094-0143(21)00489-4","volume":"20","author":"A Yagoda","year":"1993","unstructured":"Yagoda, A., Petrylak, D. & Thompson, S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am. 20, 303\u2013321 (1993).","journal-title":"Urol. Clin. North Am."},{"key":"4157_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N. Engl. J. Med. 390, 1359\u20131371 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4157_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653358","volume":"12","author":"E Lin","year":"2021","unstructured":"Lin, E. et al. Roles of the dynamic tumor immune microenvironment in the individualized treatment of advanced clear cell renal cell carcinoma. Front. Immunol. 12, 653358 (2021).","journal-title":"Front. Immunol."},{"key":"4157_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"4157_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"4157_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1061394","volume":"13","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. TGF-\u03b2: a novel predictor and target for anti-PD-1\/PD-L1 therapy. Front. Immunol. 13, 1061394 (2022).","journal-title":"Front. Immunol."},{"key":"4157_CR14","doi-asserted-by":"publisher","first-page":"100755","DOI":"10.1016\/j.omto.2023.100755","volume":"31","author":"M Shou","year":"2023","unstructured":"Shou, M., Zhou, H. & Ma, L. New advances in cancer therapy targeting TGF-\u03b2 signaling pathways. Mol. Ther. Oncolytics 31, 100755 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"4157_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"4157_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay8456","volume":"12","author":"CJ Martin","year":"2020","unstructured":"Martin, C. J. et al. Selective inhibition of TGF\u03b21 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci. Transl. Med. 12, eaay8456 (2020).","journal-title":"Sci. Transl. Med."},{"key":"4157_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas, D. A. & Massagu\u00e9, J. TGF-\u03b2 directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369\u2013380 (2005).","journal-title":"Cancer Cell"},{"key":"4157_CR18","doi-asserted-by":"publisher","first-page":"1387975","DOI":"10.3389\/fimmu.2024.1387975","volume":"15","author":"Y Zong","year":"2024","unstructured":"Zong, Y., Deng, K. & Chong, W. P. Regulation of Treg cells by cytokine signaling and co-stimulatory molecules. Front. Immunol. 15, 1387975 (2024).","journal-title":"Front. Immunol."},{"key":"4157_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"4157_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"4157_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40425-018-0493-9","volume":"7","author":"E Dodagatta-Marri","year":"2019","unstructured":"Dodagatta-Marri, E. et al. \u03b1-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by \u03b1-TGF\u03b2 antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer 7, 62 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"4157_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00428-021-03256-6","volume":"480","author":"T Takahara","year":"2022","unstructured":"Takahara, T. et al. TGFB1 mRNA expression is associated with poor prognosis and specific features of inflammation in ccRCC. Virchows Arch. 480, 635\u2013643 (2022).","journal-title":"Virchows Arch."},{"key":"4157_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi, M. et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J. Hematol. Oncol. 14, 27 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"4157_CR24","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/1878-0261.13146","volume":"16","author":"JL Gulley","year":"2022","unstructured":"Gulley, J. L. et al. Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment. Mol. Oncol. 16, 2117\u20132134 (2022).","journal-title":"Mol. Oncol."},{"key":"4157_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-\u03b2 signaling in health, disease, and therapeutics. Signal Transduct. Target. Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"4157_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00280-022-04468-6","volume":"90","author":"Y Vugmeyster","year":"2022","unstructured":"Vugmeyster, Y. et al. Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1. Cancer Chemother. Pharmacol. 90, 369\u2013379 (2022).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"4157_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cell.2018.05.027","volume":"174","author":"Y Qin","year":"2018","unstructured":"Qin, Y. et al. A milieu molecule for TGF-\u03b2 required for microglia function in the nervous system. Cell 174, 156\u2013171 (2018).","journal-title":"Cell"},{"key":"4157_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.matbio.2017.11.014","volume":"71-72","author":"DB Rifkin","year":"2018","unstructured":"Rifkin, D. B., Rifkin, W. J. & Zilberberg, L. LTBPs in biology and medicine: LTBP diseases. Matrix Biol. 71-72, 90\u201399 (2018).","journal-title":"Matrix Biol."},{"key":"4157_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-017-3245-5","volume":"79","author":"AW Tolcher","year":"2017","unstructured":"Tolcher, A. W. et al. A phase 1 study of anti-TGF\u03b2 receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 79, 673\u2013680 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"4157_CR30","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho, B. C. et al. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial. J. Thorac. Oncol. 18, 1731\u20131742 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"4157_CR31","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909\u2013918 (2020).","journal-title":"Nat. Med."},{"key":"4157_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03436-1","volume":"20","author":"L Cheng","year":"2022","unstructured":"Cheng, L. et al. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. J. Transl. Med. 20, 247 (2022).","journal-title":"J. Transl. Med."},{"key":"4157_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/cas.16398","volume":"116","author":"T Wang","year":"2025","unstructured":"Wang, T. et al. PD-1 blockade treatment in melanoma: mechanism of response and tumor-intrinsic resistance. Cancer Sci. 116, 329\u2013337 (2025).","journal-title":"Cancer Sci."},{"key":"4157_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02327-y","volume":"20","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR\/MSI-H gastric adenocarcinoma. BMC Med. 20, 133 (2022).","journal-title":"BMC Med."},{"key":"4157_CR35","volume":"16","author":"R Panda","year":"2024","unstructured":"Panda, R., Mohan, S. & Vellapandian, C. Harnessing epigenetic mechanisms to overcome immune evasion in cancer: the current strategies and future directions. Cureus 16, e70631 (2024).","journal-title":"Cureus"},{"key":"4157_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","volume":"15","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J. Hematol. Oncol. 15, 47 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"4157_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4157_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40398-4","volume":"14","author":"A Castiglioni","year":"2023","unstructured":"Castiglioni, A. et al. Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nat. Commun. 14, 4703 (2023).","journal-title":"Nat. Commun."},{"key":"4157_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal, S. K. et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402, 185\u2013195 (2023).","journal-title":"Lancet"},{"key":"4157_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30202-X","volume":"19","author":"A Ribas","year":"2018","unstructured":"Ribas, A., Kirkwood, J. M. & Flaherty, K. T. Anti-PD-1 antibody treatment for melanoma. Lancet Oncol. 19, e219 (2018).","journal-title":"Lancet Oncol."},{"key":"4157_CR41","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","volume":"404","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study. Lancet 404, 1309\u20131320 (2024).","journal-title":"Lancet"},{"key":"4157_CR42","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00262-020-02563-2","volume":"69","author":"Y Qi","year":"2020","unstructured":"Qi, Y. et al. Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. Cancer Immunol. Immunother. 69, 1565\u20131576 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"4157_CR43","doi-asserted-by":"crossref","unstructured":"Ozbay Kurt, F. G., Lasser, S., Arkhypov, I., Utikal, J. & Umansky, V. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target. J. Clin. Invest. 133, e170762 (2023).","DOI":"10.1172\/JCI170762"},{"key":"4157_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104274","volume":"360","author":"C Gebhardt","year":"2021","unstructured":"Gebhardt, C. et al. Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: a pilot study. Cell Immunol. 360, 104274 (2021).","journal-title":"Cell Immunol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04157-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:57Z","timestamp":1774018977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04157-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4157"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04157-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.Y. reports consulting fees from 858 Therapeutics, AbbVie, Acrivon, Adagene, Aeneid Therapeutics, Almac, Alterome Therapeutics, Aduro Biotech, Amgen, Amphista Therapeutics, Artios, Astex, AstraZeneca, Atavistik, Athena, Atrin Pharmaceuticals, Avenzo, Avoro, AXIOM, Baptist Health System, Bayer, BeiGene, Bicycle Therapeutics, BioCity Pharma, Bloom Burton, Blueprint Medicines, Bluestar Bio, Boxer Capital, BridGene Biosciences, Bristol Myers Squibb, C4 Therapeutics, Calithera Biosciences, Cancer Research Horizons, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clasp, Clovis Oncology, Cybrexa Therapeutics, Daiichi-Sankyo, DAiNA, Dark Blue Therapeutics, Dawn Manco, Debiopharm, Diffusion Pharmaceuticals, Duke Street Bio, EcoR1 Capital, Eikon, Ellipses Pharma, EMD Serono, Entos, Flagship Pioneering, Forbion, FoRx Therapeutics AG, F-Star Therapeutics, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, Grey Wolf Therapeutics, GlaxoSmithKline, Guardant, Guidepoint, IDEAYA Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor Therapeutics, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Janssen, Jazz Pharmaceuticals, Joint Scientific Committee for Phase I Trials in Hong Kong, Kyn Therapeutics, Kyowa Kirin Pharmaceutical Development, Lumanity, MEI Pharma, Mereo BioPharma, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexus Pharmaceuticals, Nimbus, Novocure, Odyssey Therapeutics, OHSU, OncoSec, Ono Pharmaceuticals, Onxeo, Pfizer, Piper-Sandler, Pliant Therapeutics, Plexium, Prelude Therapeutics, ProLynx, Protai Bio, PSIM, Radiopharm Theranostics, Repare Therapeutics, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Stablix, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2 Theragnostics, Techspert.io, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Thryv Therapeutics, Tolremo, Tome Biosciences, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome Therapeutics, Vivace Therapeutics, Voronoi Inc, XinThera and Zai Labs. T.A.Y. also reports grant and research support from 858 Therapeutics, Accent, Aprea Therapeutics, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Boundless Bio, BridGene BioScience, Circle Pharma, Clovis Oncology, Constellation, Cancer Prevention and Research Institute of Texas, Cyteir, US Department of Defense, Eisbach Bio, Lilly, EMD Serono, Exelixis, Forbius, F-Star Therapeutics, Gilead, GlaxoSmithKline, Genentech, Golfers Against Cancer, Haihe Pharmaceutical, IDEAYA Biosciences, ImmuneSensor Therapeutics, Insilico Medicine, Ionis, Ipsen, Jounce Therapeutics, Karyopharm, KSQ, Kyowa Kirin Pharmaceutical Development, Loxo Oncology, Merck, Mirati, Novartis, National Institutes of Health\/National Cancer Institute, Pfizer, Pliant Therapeuticts, Prelude Therapeutics, Ribon Therapeutics, Regeneron, Repare Therapeutics, Roche, Rubius Therapeutics, Sanofi, Scholar Rock, Seattle Genetics, SpringWorks, Synnovation, Tango, Tesaro, V Foundation, Vivace Therapeutics, Zenith and Zentalis Pharmaceuticals. R.F.S. reports consulting fees from Astellas Pharma, AstraZeneca, AVEO Oncology, Bristol Myers Squibb, Editas Medicine, Eisai, EMD Serono, Exelixis, Gilead Sciences, Janssen, Lilly, Loxo Oncology, Mirati Therapeutics, Pfizer, Silverback Therapeutics and Seattle Genetics; institutional research support from ALX Oncology, Ascendis Pharma, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, CytomX, Eisai, Genentech\/Roche, Gilead Sciences, Immunocore, Jounce Therapeutics, Lilly, Loxo Oncology, Merck, Mirati Therapeutics, Moderna, Novartis, Pfizer, Pionyr, Pyxis, QED Therapeutics and Scholar Rock; equity in AbbVie; and the following patent: Neo-Antigens in Cancer (PCT\/US2020\/031357). U.V. reports grants and consulting fees from Merck; grants from Astellas Pharma and Bristol Myers Squibb; and consulting fees from Astellas Pharma, Bayer, Bristol Myers Squibb, Exelixis, Mural Oncology, Novartis, Pfizer and Xencor. J.F.G. reports personal fees and other support from Adaptimmune, AI Proteins, Alexo Therapeutics, Array Biopharma, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech\/Roche, Merck, Moderna, Palleon Pharmaceuticals and Tesaro; equity in AI Proteins, Alkeus Pharmaceuticals and Ironwood Pharmaceuticals (spouse); personal fees from AstraZeneca, Bristol Myers Squibb, Genentech\/Roche, Gilead Sciences, iTeos Therapeutics, Janssen, Jounce Therapeutics, Karyopharm, Lilly, Mariana Therapeutics, Merus Pharmaceuticals, Mirati Therapeutics, Novocure, Nuvalent, Pfizer, Sanofi, Silverback Therapeutics and Takeda; and grants, personal fees and other support from Novartis. J.F.G. has an immediate family member who is an employee with equity in Alkeus Pharmaceuticals. M.M. reports consultancy for Castle Biosciences, Eisai, IQVIA, Merck, Moderna and Pfizer. M.M. also reports research funding from Aadi Biosciences, Alpine Immune Sciences, Arcus Biosciences, Arvinas, Ascentage Pharma, American Society of Clinical Oncology, Astellas Pharma, Aulos Bioscience, Bayer, Bicycle Therapeutics, Biomed Valley Discoveries, BioNTech, Bristol Myers Squibb, C4 Therapeutics, Dragonfly Therapeutics, EMD Serono, Epizyme, Erasca, Exelixis, Foghorn Therapeutics, G1 Therapeutics, Genentech\/Roche, Gilead Sciences, GlaxoSmithKline, IDEAYA Biosciences, Ikena Oncology, ImmVira Pharma, Infinity Pharmaceuticals, Jacobio Pharmaceuticals, Kechow Pharma, Kezar Life Sciences, Kinnate BioPharma, MedImmune, Mereo BioPharma, Metabomed, Moderna, NBE Therapeutics, Nektar Therapeutics, Novartis, NucMito Pharmaceuticals, OncoC4, Oncorus, OnKure Therapeutics, PACT Pharma, Pfizer, Plexxikon, Poseida Therapeutics, Prelude Therapeutics, Pyramid Biosciences, Regeneron Pharmaceuticals, Sapience Therapeutics, Scholar Rock, Seattle Genetics, Synthorx, Tempest Therapeutics, Teneobio, Tizona Therapeutics, Tmunity Therapeutics, TopAlliance Biosciences and Xilio Therapeutics. M.B. reports personal fees from Tempus Labs and personal fees from Texas Oncology outside the submitted work. A.A.T. reports consulting or advisory roles for Bayer, BioNTech, Bristol Myers Squibb, Clinigen, ConcertAI, Eisai, Genentech\/Roche, Instil Bio, Merck, Novartis, Partner Therapeutics and Sanofi\/Regeneron Pharmaceuticals and has received institutional research funding from Acrotech Biopharma, Agenus, Bristol Myers Squibb, Clinigen, Genentech\/Roche, InflaRx, Merck, OncoSec, Pfizer, Sanofi\/Regeneron Pharmaceuticals and Scholar Rock. B.B. reports research funding from Agenus and NanoView Biosciences, travel expenses from Agenus and Erytech Pharma and advisory board and consulting for BioLineRx, Blueprint Medicines and Enlivex. G.S. reports serving on advisory boards for Aktis Oncology, Astellas Pharma, AstraZeneca, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi-Sankyo, Ellipses Pharma, EMD Serono, Exelixis, G1 Therapeutics, Genentech, Gilead Sciences, Janssen, Lilly\/Loxo Oncology, Merck, Pfizer, Sanofi, Scholar Rock, Servier and Tempus; receiving institutional research support from Bayer, Blue Earth Diagnostics, EMD Serono, Exelixis and Sumitomo Pharma; receiving speaker\u2019s fees from AstraZeneca, AVEO Oncology, Bayer, Exelixis, Gilead Sciences, Janssen, Natera, Pfizer and Seagen; receiving data safety monitoring committee honorarium from Mereo BioPharma; and receiving writing\/editing fees from Onviv, Practice Update and UpToDate. G.S. also has a spouse employed by Exact Sciences and Myriad Genetics and received travel costs from Astellas Pharma and Bristol Myers Squibb. D.K., D.P. and S.B. have no disclosures to report. Y.J., L.L., S.H., G.T., S.D., M.Q., J.M. and L.G. are employees of Scholar Rock.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}